
TB-500
Also called thymosin beta-4 fragment
- Evidence
- Limited research
- Class
- Synthetic Tβ4 fragment
TB-500 belongs to the Synthetic Tβ4 fragment class. This library groups it under bones & muscles. Its source category is Not FDA-approved.
At a glance
| Compound class | Synthetic Tβ4 fragment |
|---|---|
| Body system | Bones & muscles |
| Use or research focus | Soft-tissue injury, recovery |
| Regulatory status | Not FDA-approved; PCAC voted favorably (Jul 2026) for 503A compounding — final FDA rule pending |
| Source evidence rating | Limited research |
How does TB-500 work?
Upregulates actin; promotes cell migration, angiogenesis, repair.
The source catalog maps this mechanism to Joints / Connective tissue, Muscle. A biological mechanism describes how a compound interacts with the body; it does not by itself prove a clinical benefit.
What does the evidence tell us?
The source catalog rates the evidence as limited. Laboratory and animal findings cannot establish benefits or safety in people. Small or early studies may raise useful research questions without supporting routine clinical use.
Use the Citations tab to examine the underlying sources. Look for human studies, a relevant comparison group, meaningful outcomes, and adequate follow-up. An ingredient, approved drug, and compounded preparation may have different evidence.
Safety and considerations
For an unapproved use or compound, safety and effectiveness may be uncertain. Products sold for research are not a substitute for prescribed care. Do not infer a human dose, injection protocol, or treatment recommendation from preclinical research.
This library is educational and does not provide dosing or treatment instructions. A listing here does not indicate that Peppy offers the compound.
Common questions
What is TB-500?
TB-500 belongs to the Synthetic Tβ4 fragment class. This library groups it under bones & muscles. Its source category is Not FDA-approved. Its recorded use or research focus is: Soft-tissue injury, recovery.
Is TB-500 FDA-approved?
The catalog records: Not FDA-approved; PCAC voted favorably (Jul 2026) for 503A compounding — final FDA rule pending. Check the current product-specific regulatory information in the source links; a source category does not establish approval for every use or formulation.
How strong is the research?
The source catalog rates the evidence as limited. Laboratory and animal findings cannot establish benefits or safety in people. Small or early studies may raise useful research questions without supporting routine clinical use.
Where can I read the research?
The Citations tab contains 10 reference links from the source dataset. The original research guide provides additional context. These links are a starting point for reading the evidence.
More for bones & muscles
Factual catalog fields and citation links are adapted from Superpower’s TB-500 guide and the public dataset linked in the reference post. Peppy’s explanations are educational; this page does not represent an independent clinical review of every linked study.
Sources & further reading
References associated with TB-500 in the source dataset. Open a source to review its study design, population, limitations, and date.
- 01review of the full-length protein's regenerative biologydoi.org
- 02voted 8-6, with one abstention, to recommend TB-500mcdermottlaw.com
- 03randomized dose-escalation venous-ulcer studypubmed.ncbi.nlm.nih.gov
- 04Phase III eye-drop trial in neurotrophic keratopathypubmed.ncbi.nlm.nih.gov
- 05DOI: 10.1196/annals.1415.003doi.org
- 06identified and characterizedpubmed.ncbi.nlm.nih.gov
- 07FDA has removed it from Category 2fda.gov
- 08Detection methods for TB-500pubmed.ncbi.nlm.nih.gov
- 092024 equine population studypubmed.ncbi.nlm.nih.gov
- 10voted 8-6 to recommend TB-500statnews.com





